(R)-CR8

Key Product Details

Product Description

(R)-CR8 is a cyclin dependent kinase (cdk) inhibitor (reported IC₅₀ values are 0.036 - 0.07, 0.09 - 0.8, 0.13 - 0.68, 0.18 - 1 and >1 μM for cdk2, cdk1, cdk5, cdk9 and cdk7, respectively). Also inhibits casein kinase 1 (CK1; IC₅₀ = 0.6 μM). Acts as molecular glue; forms a complex between CDK12-cyclin K and the CUL4 adapter protein DDB1 resulting in ubiquination and degradation of cyclin K.

Product Specifications for (R)-CR8

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for (R)-CR8

The following data is based on the product molecular weight 540.92.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.85 mL	9.24 mL	18.49 mL
5 mM	0.37 mL	1.85 mL	3.70 mL
10 mM	0.18 mL	0.92 mL	1.85 mL
50 mM	0.04 mL	0.18 mL	0.37 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 16 publications citing the usage of this product.

• Jorda How selective are pharmacological inhibitors of cell-cycle-regulating cyclin-dependent kinases? J.Med.Chem. 2018 PMID: 30234987
• Słabicki The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 2020 PMID: 32494016
• Oumata Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J.Med.Chem. 2008 PMID: 18698753

Product Documents for (R)-CR8